NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
Relative value
$84.0
Overvalued (Relative Value)
64.7%
NTM P/E
(106.8x)
Peer set median: 12.6x
1Y Fwd EV/EBITDA
(14.3x)
Peer set median: 10.7x
Stock quality
6/10
Good
ALNY Relative Value & Intrinsic Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY Valuation Multiples comparison vs Peer Set
Crunching data... Almost there!
ALNY Valuation multiples overview
Crunching data... Almost there!
ALNY Valuation multiples history vs. Peer set
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
DCF value calculator
Peter Lynch Fair Value
Earnings Power Value
Intrinsic Value
Reverse DCF
Margin of safety
Peter Lynch charts
Earnings growth model
Ben Graham Fair Value
Discount rate
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc. relative value?
As of Jan 10, 2025, Apple Relative Value is $84.0. This suggests it may be overvalued by 64.7% compared to its current price of around $238.0.
What is Alnylam Pharmaceuticals, Inc. DCF (discounted cash flow) valuation?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $238.0, using a discount rate of 7.8% and terminal growth rate of 3.0%.
What is Alnylam Pharmaceuticals, Inc. intrinsic value?
As of Jan 10, 2025, Apple Intrinsic Value is $84.9. This suggests it may be overvalued by 64.3% compared to its current price of around $238.0.